Cellectis Announces Presentations at Upcoming Conferences

NEW YORK--(BUSINESS WIRE)--

Regulatory News:

Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on the development of gene edited, next generation CAR T-cell product candidates for the treatment of cancer, today announced presentations at the following upcoming banking conferences and events:

Goldman Sachs Biotech and Emerging Pharma SymposiumLondon, September 11, 2015

Bank of America Merrill Lynch Global Healthcare ConferenceLondon, September 16, 2015 (Presentation time: 9:45AM)

Morgan Stanley Global Healthcare ConferenceNew York City, September 18, 2015

Cellectis Investor and Analyst Day NYCNew York City, September 22, 2015 (Presentation time: 8:00AM)

Ladenburg Thalmann Healthcare ConferenceNew York City, September 29, 2015 (Presentation time: 4:00PM)

Leerink Immuno-Oncology RoundtableNew York City, October 1, 2015

Cellectis Investor and Shareholder Day ParisParis, October 5, 2015 (Presentation time: 6:00PM)

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

TALEN® is a registered trademark owned by the Cellectis Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150909006690/en/

Media
Jennifer Moore, VP Communications
Phone: 917-580-1088
email: [email protected]
or
Caitlin Kasunich / Dixon Moretz
KCSA Strategic Communications
212.896.1241 / 212.896.1251
[email protected] / [email protected]
or
Investor relations:
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: [email protected]

Source: Cellectis

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• Celyad Oncology Announces €500,000 Private Placement
• First Energy Africa Oil Corp. Strengthens Board with Appointment of Industry Veterans Simon Akit and Frederick Kozak